Pre-Close Trading Update

RNS Number : 5747R
Advanced Medical Solutions Grp PLC
30 June 2015
 

30 June 2015

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

Pre-Close Trading Update

 

Winsford, UK, 30 June 2015 - Advanced Medical Solutions Group plc (AIM: AMS.L), the surgical and advanced woundcare specialist company, today announces an update on trading prior to its close period for the half year ended 30 June 2015.

 

The Board confirms that trading for the half year is in line with the Board's expectations and currently expects both revenue and profitability for the full year 2015 to be in line with present market expectations.

 

Chris Meredith, Chief Executive Officer of AMS, commented: "The Board is pleased with the ongoing good performance of the business. We continue to gain market share with our high quality products by delivering innovation to patients and surgeons."

 

- Ends -

 

 

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director

 

 

 

+44 (0) 1606 545508

 

Consilium Strategic Communications

Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys

 

 

+44 (0) 20 3709 5700

AMS@consilium-comms.com

 

Investec Bank PLC (NOMAD & Broker)

Gary Clarence / Daniel Adams / Patrick Robb

 

 

+44 (0) 20 7597 5970

 

About Advanced Medical Solutions Group plc - see www.admedsol.com 

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 65 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 470 employees. For more information please see www.admedsol.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLLFERRVIAFIE
UK 100